CompletedNot Applicable

Complementary Intervention for COVID-19

Egypt50 participantsStarted 2020-01-01

Plain-language summary

Boswellia Serrata gum and Licorice extract are two nutritional agents that have pharmacological actions that could support the medical intervention for COVID-19. They have broad antiviral activity, anti-inflammatory, anti-lung injury, antibacterial activity, antithrombic formation, and immunomodulatory activity. The study will be conducted after January 18, 2017

Who can participate

Age range12 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Symptomatic and laboratory-confirmed diagnosis of COVID-19. * RT-PCR indicates positive for novel coronavirus RNA * Viral specific IgM and IgG are detectable in serum * Viral specific IgG is detectable from negative to positive, OR * Viral specific IgG antibody reaches a titration of at least 4-fold higher in the recovery stage than in the acute stage Exclusion Criteria: * Patients who are not fulfilling the diagnostic criteria for COVOID-19. * Pregnant women. * Critically ill patients who are mechanically ventilated since admission. * Hypertensive patients. * Congestive heart failure patients

What they're measuring

Increased number of people recovering from COVID-19

Timeframe: 14 days

Trial details

NCT IDNCT04487964

SponsorEgyptian Biomedical Research Network

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2021-11-01

View on ClinicalTrials.gov More COVID-19 trials